AbbVie strikes $10.9 billion deal for Apogee Therapeutics
22/06/2026 12:02
AbbVie strikes $10.9 billion deal for Apogee Therapeutics June 22 (Reuters) - AbbVie ABBV.N will acquire biotech Apogee Therapeutics APGE.O for $10.9 billion in cash, they said on Monday, as the company builds its next-generation immunology pipeline.
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sriraj Kalluvila)
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement